Payment overview · 2025
General Payments
$240.82
13 reported records · 8 companies
Healthcare provider profile · identity verified
Dakota L Gilbert
Allopathic & Osteopathic Physicians|Family Medicine · HILLSBORO, IL · NPI 1023515921
Verified facts
What the public records show
CMS Open Payments records show Dakota L Gilbert received $240.82 in general payments during 2025 across 13 reported records.
Amgen Inc. accounted for 22.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 127 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $54.28 | 22.5% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $36.71 | 15.2% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $36.64 | 15.2% | 2 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $33.22 | 13.8% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $22.41 | 9.3% | 1 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $19.67 | 8.2% | 1 | 2025 |
| Tactile Systems Technology Inc | Unresolved — no canonical attribution shown | $19.13 | 7.9% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $18.76 | 7.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $240.82 | 13 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $54.28 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $36.64 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $36.27 | 2 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $33.22 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $22.41 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $22.41 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $21.64 | 1 | 2025 |
Source payment records
|
|||||
| BEYFORTUS Normalized: beyfortus |
Biological | SANOFI PASTEUR INC. | $19.67 | 1 | 2025 |
Source payment records
|
|||||
| Flexitouch Plus Normalized: flexitouch plus |
Device | Tactile Systems Technology Inc | $19.13 | 1 | 2025 |
Source payment records
|
|||||
| Nimbl Normalized: nimbl |
Device | Tactile Systems Technology Inc | $19.13 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $18.76 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $15.07 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 34 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
127 | 27 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 496 | 144 |
| Amlodipine Besylate | Amlodipine Besylate | 360 | 95 |
| Metoprolol Succinate | Metoprolol Succinate | 306 | 74 |
| Lisinopril | Lisinopril | 304 | 88 |
| Omeprazole | Omeprazole | 296 | 89 |
| Losartan Potassium | Losartan Potassium | 274 | 75 |
| Furosemide | Furosemide | 233 | 62 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 213 | 44 |
| Tamsulosin Hcl | Tamsulosin Hcl | 212 | 53 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 210 | 71 |
| Levothyroxine Sodium | Levothyroxine Sodium | 202 | 50 |
| Potassium Chloride | Potassium Chloride | 199 | 52 |
| Pantoprazole Sodium | Pantoprazole Sodium | 190 | 54 |
| Warfarin Sodium | Warfarin Sodium | 185 | 16 |
| Gabapentin | Gabapentin | 183 | 41 |
| Metformin Hcl | Metformin Hcl | 183 | 43 |
| Pravastatin Sodium | Pravastatin Sodium | 164 | 41 |
| Hydrochlorothiazide | Hydrochlorothiazide | 163 | 42 |
| Duloxetine Hcl | Duloxetine Hcl | 142 | 25 |
| Metoprolol Tartrate | Metoprolol Tartrate | 139 | 38 |
| Alprazolam | Alprazolam | 134 | 25 |
| Montelukast Sodium | Montelukast Sodium | 131 | 29 |
| Metformin Hcl Er | Metformin Hcl | 129 | 36 |
| Jardiance | Empagliflozin | 127 | 27 |
| Allopurinol | Allopurinol | 108 | 24 |
| Trazodone Hcl | Trazodone Hcl | 105 | 25 |
| Tramadol Hcl | Tramadol Hcl | 101 | 27 |
| Sertraline Hcl | Sertraline Hcl | 96 | 25 |
| Carvedilol | Carvedilol | 94 | 24 |
| Famotidine | Famotidine | 94 | 28 |
| Eliquis | Apixaban | 86 | 22 |
| Fluticasone Propionate | Fluticasone Propionate | 84 | 35 |
| Quetiapine Fumarate | Quetiapine Fumarate | 82 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 78 | 21 |
| Simvastatin | Simvastatin | 77 | 22 |
| Glipizide Er | Glipizide | 74 | 16 |
| Clonazepam | Clonazepam | 72 | 11 |
| Clopidogrel | Clopidogrel Bisulfate | 72 | 21 |
| Prednisone | Prednisone | 71 | 56 |
| Mirtazapine | Mirtazapine | 68 | 13 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 68 | 20 |
| Meloxicam | Meloxicam | 67 | 17 |
| Finasteride | Finasteride | 60 | 17 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 59 | 11 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 57 | 14 |
| Lorazepam | Lorazepam | 57 | 14 |
| Spironolactone | Spironolactone | 55 | 17 |
| Citalopram Hbr | Citalopram Hydrobromide | 54 | 12 |
| Pregabalin | Pregabalin | 53 | 12 |
| Ozempic | Semaglutide | 52 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 52 | 12 |
| Atenolol | Atenolol | 51 | 13 |
| Amitriptyline Hcl | Amitriptyline Hcl | 50 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 48 | suppressed |
| Lovastatin | Lovastatin | 45 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 40 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 39 | suppressed |
| Glipizide | Glipizide | 38 | 12 |
| Bupropion Xl | Bupropion Hcl | 37 | 11 |
| Donepezil Hcl | Donepezil Hcl | 36 | suppressed |
| Lamotrigine | Lamotrigine | 36 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 36 | 12 |
| Diclofenac Sodium | Diclofenac Sodium | 35 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 34 | suppressed |
| Mounjaro | Tirzepatide | 34 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 34 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 33 | suppressed |
| Ezetimibe | Ezetimibe | 32 | suppressed |
| Trulicity | Dulaglutide | 32 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 31 | 11 |
| Ibuprofen | Ibuprofen | 31 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 31 | 12 |
| Olanzapine | Olanzapine | 30 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 30 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 29 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Rybelsus | Semaglutide | 28 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 27 | 24 |
| Doxycycline Hyclate | Doxycycline Hyclate | 27 | 22 |
| Ropinirole Hcl | Ropinirole Hcl | 27 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 26 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 26 | suppressed |
| Cephalexin | Cephalexin | 26 | 14 |
| Hydralazine Hcl | Hydralazine Hcl | 26 | suppressed |
| Chlorthalidone | Chlorthalidone | 25 | suppressed |
| Myrbetriq | Mirabegron | 25 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 25 | suppressed |
| Azithromycin | Azithromycin | 24 | 21 |
| Memantine Hcl | Memantine Hcl | 24 | suppressed |
| Glimepiride | Glimepiride | 23 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 23 | 11 |
| Xarelto | Rivaroxaban | 23 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 22 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 21 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 21 | suppressed |
| Topiramate | Topiramate | 21 | suppressed |
| Torsemide | Torsemide | 21 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 20 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 20 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 19 | suppressed |
| Fentanyl | Fentanyl | 19 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 19 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 18 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 18 | suppressed |
| Levetiracetam | Levetiracetam | 18 | suppressed |
| Temazepam | Temazepam | 18 | suppressed |
| Valsartan | Valsartan | 18 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 17 | suppressed |
| Januvia | Sitagliptin Phosphate | 17 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 16 | suppressed |
| Celecoxib | Celecoxib | 16 | suppressed |
| Diazepam | Diazepam | 16 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Aripiprazole | Aripiprazole | 15 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 15 | suppressed |
| Nifedipine Er | Nifedipine | 15 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 15 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 15 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 14 | 11 |
| Digoxin | Digoxin | 14 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 14 | suppressed |
| Entresto | Sacubitril/Valsartan | 14 | suppressed |
| Irbesartan | Irbesartan | 14 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Novolog | Insulin Aspart | 14 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 14 | suppressed |
| Risperidone | Risperidone | 14 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 14 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 14 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Clotrimazole | Clotrimazole | 13 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 13 | suppressed |
| Ketoconazole | Ketoconazole | 13 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 13 | suppressed |
| Carbamazepine | Carbamazepine | 12 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 12 | suppressed |
| Fenofibrate | Fenofibrate | 12 | suppressed |
| Fluconazole | Fluconazole | 12 | suppressed |
| Humalog | Insulin Lispro | 12 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 12 | suppressed |
| Naproxen | Naproxen | 12 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 12 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Klor-Con M20 | Potassium Chloride | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Trueplus Insulin Syringe | Syringe And Needle,insulin,1ml | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $240.82 · 13 records | Amgen Inc. | BEYFORTUS, BREZTRI, Cologuard Collection Kit, FARXIGA, Flexitouch Plus, Korlym, MOUNJARO, Nimbl, OTEZLA, REPATHA, REXULTI, ZEPBOUND | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error